{"entity":{"id":"nct05019690","kind":"trial","name":"Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer","aka":[],"tldr":"A phase 1/2 trial of rivoceranib (apatinib) and nab-paclitaxel in triple-negative breast cancer, run by Fujian Cancer Hospital, now recruiting.","summary":"Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer is a phase 1/2, interventional study registered as NCT05019690 by Fujian Cancer Hospital, with a registry enrolment figure of 29 participants, started 2021-10-01 and due to reach its primary completion in 2024-12-01. Interventions recorded: Apatinib Mesylate; Albumin-Bound Paclitaxel. Conditions listed: Advanced Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: \"Histologically or pathologically confirmed advanced triple-negative breast cancer that meets the following criteria:\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05019690","url":"https://clinicaltrials.gov/study/NCT05019690"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-metastatic"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["rivoceranib","nab-paclitaxel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05019690","phase":"1/2","setting":"Apatinib Mesylate Combined with Albumin-bound Paclitaxel for Second-line Treatment of Advanced Triple Negative Breast Cancer:a Single-arm,exploratory Clinical Study","sponsor":"Fujian Cancer Hospital","enrolled":29,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05019690/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/"},{"id":"rivoceranib","kind":"drug","name":"Rivoceranib (apatinib)","route":"/drugs/rivoceranib/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}